Supervisory board

DGAP-News: CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Retrieved on: 
Monday, January 17, 2022 - 12:04pm
Technology, RNA, COVID-19, Degenerative disease, CureVac, Protein, Leadership, Nasdaq, Infection, GSK, Supervisory board, Therapy, Mariola, Personality, Cell biology, CVAC, RNA transfection, Senior, Management, Vaccine

Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.

Key Points: 
  • Further development of CureVac's unique mRNA technology platform will be led by Dr. Igor Splawski, Chief Scientific Officer of CureVac, and spearheaded by Dr. Patrick Baumhof, Senior Vice President Technology, who has a 15-year scientific tenure with the company.
  • "Mariola's dedication and expertise helped to build CureVac and fundamentally contributed to the advancement of mRNA technology as a whole."
  • "Mariola's groundbreaking work and innovations in mRNA technology have strongly contributed to CureVac becoming the world's pioneering company to harness mRNA for medical purposes," added Dr. Franz-Werner Haas, Chief Executive Officer of CureVac.
  • Mariola Fotin-Mleczek joined CureVac in May 2006 and became a member of the management board in 2013, first as Chief Scientific Officer and as Chief Technology Officer in 2018.

DGAP-News: Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank

Retrieved on: 
Friday, January 14, 2022 - 3:06pm
Financial Oversight and Management Board for Puerto Rico, Supervisory board, Aareal Bank, Development finance institution, Palatine Higher Regional Court, Deutsche Postbank, Deutsche Post, Bank, Deutsche Hypothekenbank, Deutsche Bank, DB, Deloitte, Company, Pfandbrief, Portigon Financial Services, General counsel, University of Bayreuth, University, Security (finance), Property management, Pension fund

Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank

Key Points: 
  • Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank
    The issuer is solely responsible for the content of this announcement.
  • Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank
    - Prof. Dr Hermann Wagner: "We welcome the decision taken by the Higher Regional Court.
  • Wiesbaden, 14 January 2022 - With a binding decision, the Frankfurt/Main Higher Regional Court approved the application submitted by Aareal Bank to appoint Messrs Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis as members of Aareal Bank's Supervisory Board, with immediate effect.
  • Prof. Dr Hermann Wagner, the Chairman of the Supervisory Board of Aareal Bank AG, commented: "We welcome the decision taken by the Higher Regional Court.

HORNBACH Holding announces start of acceptance period for public delisting offer for HORNBACH Baumarkt

Retrieved on: 
Friday, January 14, 2022 - 11:35am
Home Goods, Other Retail, Retail, Professional Services, Other Professional Services, Supervisory board, Intention, TAS, INTO, Documentation, Results of the 2013 German federal election, IPO, National instrument, Group, DIY, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, CET, Federal Financial Supervisory Authority, NOT, CEO, Review, FOR, Management, Federal republic, Board, Acquisition, Bank, Cryptocurrency, Security (finance)

HORNBACH Baumarkt shareholders can accept the delisting offer by tendering their shares at an offer price of 47.50 in cash per HORNBACH Baumarkt share.

Key Points: 
  • HORNBACH Baumarkt shareholders can accept the delisting offer by tendering their shares at an offer price of 47.50 in cash per HORNBACH Baumarkt share.
  • the last close prior to the ad hoc announcement from HORNBACH Holding confirming its intention to take HORNBACH Baumarkt private.
  • HORNBACH Baumarkt shareholders who wish to accept the delisting tender offer should contact their respective custodian bank or any other securities services company where their HORNBACH Baumarkt shares are being held.
  • Albrecht Hornbach, CEO of HORNBACH Holding, says: We encourage all HORNBACH Baumarkt shareholders to accept our attractive offer prior to HORNBACH Baumarkt being delisted from the regulated market.

DGAP-News: HORNBACH Holding announces start of acceptance period for public delisting offer for HORNBACH Baumarkt

Retrieved on: 
Friday, January 14, 2022 - 11:04am
Supervisory board, Intention, TAS, INTO, 2013 German federal election, Palatinate, IPO, Group, DIY, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, CET, Federal Financial Supervisory Authority, CEO, Review, Management, Board, Acquisition, Security (finance), Cryptocurrency

HORNBACH Holding AG & Co. KGaA ("HORNBACH Holding") announces the publication of the offer document for the public delisting tender offer to all shareholders of HORNBACH Baumarkt AG ("HORNBACH Baumarkt"), for the acquisition of all outstanding shares not already held by HORNBACH Holding, following the approval by the German Federal Financial Supervisory Authority ("BaFin").

Key Points: 
  • HORNBACH Holding AG & Co. KGaA ("HORNBACH Holding") announces the publication of the offer document for the public delisting tender offer to all shareholders of HORNBACH Baumarkt AG ("HORNBACH Baumarkt"), for the acquisition of all outstanding shares not already held by HORNBACH Holding, following the approval by the German Federal Financial Supervisory Authority ("BaFin").
  • HORNBACH Baumarkt shareholders can accept the delisting offer by tendering their shares at an offer price of 47.50 in cash per HORNBACH Baumarkt share.
  • HORNBACH Baumarkt shareholders who wish to accept the delisting tender offer should contact their respective custodian bank or any other securities services company where their HORNBACH Baumarkt shares are being held.
  • Albrecht Hornbach, CEO of HORNBACH Holding, says: "We encourage all HORNBACH Baumarkt shareholders to accept our attractive offer prior to HORNBACH Baumarkt being delisted from the regulated market.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am
Medicine, Patient, Research, Financial Oversight and Management Board for Puerto Rico, Supervisory board, Drug discovery, Van Lanschot Kempen, Chief scientific officer, R, UCB, Corporation, RNA, Radboud University Nijmegen, Knowledge, Gilead Sciences, CEO, Roche, National Institute, Review, Medical University of Lublin, Paul, European Society of Gynaecological Oncology, Industry, Therapy, Pharmacology, Company, Drug development, University of Antwerp, Doctor of Philosophy, Kempen, Foundation for the National Institutes of Health, RNA transfection, Neurology, Director, University, Board, Investment, Medical school, Pharmaceutical industry, Fine chemical, Galápagos Islands

These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am
Medicine, Patient, Research, Financial Oversight and Management Board for Puerto Rico, Supervisory board, Drug discovery, Van Lanschot Kempen, Chief scientific officer, R, UCB, Corporation, RNA, Radboud University Nijmegen, Knowledge, Gilead Sciences, CEO, Roche, National Institute, Review, Medical University of Lublin, Paul, European Society of Gynaecological Oncology, Industry, Therapy, Pharmacology, Company, Drug development, University of Antwerp, Doctor of Philosophy, Kempen, Foundation for the National Institutes of Health, RNA transfection, Neurology, Director, University, Board, Investment, Medical school, Pharmaceutical industry, Fine chemical, Galápagos Islands

WARSAW, Poland, Jan. 14, 2022 /PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and unexplored protein targets to treat multiple incurable diseases, announces the appointment of Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński to its Supervisory Board. These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

DGAP-News: dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.

Retrieved on: 
Thursday, January 13, 2022 - 10:08pm
U.S. Securities and Exchange Commission, Vaccine, SAP, KfW, Biotechnology, Neurodegeneration, SEC, Gesellschaft mit beschränkter Haftung, Spanish mythology, Ownership, Nasdaq, DGAP, Supervisory board, DBH Deutsche Buch Handels GmbH & Co. KG, News, Therapy, Cancer, Hopp, CVAC, Kommanditgesellschaft, Securities Act of 1933, Federal republic, Investment, Security (finance), Property management, CureVac

DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG

Key Points: 
  • DGAP-News: dievini Hopp BioTech holding GmbH & Co. KG
    dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
  • dievini and The Federal Republic of Germany amend shareholders' agreement regarding investments in CureVac N.V.
    WALLDORF / BERLIN , Germany - 13 January 2022 - Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt fr Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (Nasdaq: CVAC).
  • In due course and solely to finance the restructuring (including tax obligations for involved parties), dievini intends to sell CureVac common shares.
  • Apart from this, dievini, Dietmar Hopp and his holding company, DH-LT-Investments, as well as the Federal Republic of Germany currently do not plan to sell CureVac common shares to third parties.

VIA optronics AG Announces Changes to the Committee Composition of the Company’s Supervisory Board

Retrieved on: 
Thursday, January 13, 2022 - 9:16pm
Consumer Electronics, Technology, Audio, Video, Software, Internet, Hardware, U.S. Securities and Exchange Commission, Supervisory board, PDF, Shock, Audit committee, NYSE, Financial compensation, Solution, Vibration, Annual, Nomination, Company, Mark (given name), The Annual Report, Mission statement, Annual general meeting, Annual report, Animal, Television, VIA

VIA optronics AG (NYSE: VIAO) (VIA or the Company), a leading supplier of interactive display systems and solutions, today announced changes to the committee composition of its Supervisory Board.

Key Points: 
  • VIA optronics AG (NYSE: VIAO) (VIA or the Company), a leading supplier of interactive display systems and solutions, today announced changes to the committee composition of its Supervisory Board.
  • Anthony John Best and Anil Doradla will continue to serve on the Nomination and Compensation Committee.
  • Additionally, Arthur Tan began serving as Chairperson on the Nomination and Compensation Committee effective December 29, 2021.
  • Dr. Heiko Frank will continue to serve on the Supervisory Board as Chairperson with Arthur Tan as his deputy.

DGAP-News: Aareon CEO Dr Manfred Alflen has announced his retirement from the operating business in March 2022 - Hartmut Thomsen to take over as Chairman of the Management Board

Retrieved on: 
Thursday, January 13, 2022 - 10:03am
Supervisory board, Financial Oversight and Management Board for Puerto Rico, Siemens Nixdorf Informationssysteme, SAP, IBM, Growth, Advent International, Aareal Bank, Leadership, Housing, Industry, Company, ERP, Software, Public relations, Oracle

Wiesbaden/Mainz, 13 January 2022 - Dr Manfred Alflen (61), Chairman of the Management Board of Aareon AG, has announced that he will retire from the operating business with effect from 31 March 2022.

Key Points: 
  • Wiesbaden/Mainz, 13 January 2022 - Dr Manfred Alflen (61), Chairman of the Management Board of Aareon AG, has announced that he will retire from the operating business with effect from 31 March 2022.
  • Aareon AG's Supervisory Board has appointed Hartmut Thomsen (50) as Dr Alflen's successor, effective 1 April 2022.
  • I will remain close to Aareon, but no longer wish to be engaged in its operating business.
  • On behalf of the entire Supervisory Board, I would like to express our heartfelt thanks to Dr Alflen and his team.

Metalloinvest announces the election of a new Board of Directors

Retrieved on: 
Thursday, January 13, 2022 - 8:02am
Telecom, Exchequer and Audit Departments Act 1866, KPMG, First, KPMG tax shelter fraud, CEO, Strategy, CIS, Copper, Internal audit, HBI, Supervisory board, Board of directors, USM, Technology, Director, Board, Control, Management

Moscow, Russia - 13 January 2022 - Metalloinvest, a leading global iron ore and HBI producer and supplier, and one of the regional producers of high-quality steel, announces the election of a new Board of Directors at Management Company Metalloinvest.

Key Points: 
  • Moscow, Russia - 13 January 2022 - Metalloinvest, a leading global iron ore and HBI producer and supplier, and one of the regional producers of high-quality steel, announces the election of a new Board of Directors at Management Company Metalloinvest.
  • Yerkozha Akylbek was elected to the Board of Directors for the first time, replacing Maxim Poletaev.
  • He also serves on the Board of Directors of Udokan Copper and is Chairman of the Supervisory Board of Coscom.
  • The Board of Directors of Management Company Metalloinvest comprises the following 12 members:
    Ivan Streshinsky, Chairman of the Board of Directors;
    Vakhtang Kocharov, Vice Chairman of the Board of Directors, Executive Director;